Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 11/20 | 0.56 |
| ▸ | TGM2 | P21980 | 1/20 | 0.54 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.47 |
| ▸ | POLG | P54098 | 1/20 | 0.46 |
| ▸ | HINT1 | P49773 | 1/20 | 0.45 |
| ▸ | PNP | P00491 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29093384 | 0.82 | TGM2 (0.58) | KRASTGM2FUT5NT5EPOLB | |
| SCHEMBL29657998 | 0.81 | KRAS (0.65) | KRASTGM2FUT5NT5EP2RY2 | |
| SCHEMBL30576907 | 0.81 | KRAS (0.65) | KRASTGM2FUT5NT5EP2RY2 | |
| SCHEMBL31359443 | 0.80 | TGM2 (0.56) | KRASTGM2FUT5NT5EPOLB | |
| SCHEMBL29216807 | 0.80 | TGM2 (0.49) | KRASTGM2FUT5NT5EPOLB | |
| SCHEMBL29793878 | 0.80 | KRAS (0.64) | KRASTGM2FUT5NT5EP2RY2 | |
| Gtp SCHEMBL3333959 | 0.77 | TGM2 (0.81) | KRASTGM2FUT5NT5EP2RY2 | |
| SCHEMBL19691775 | 0.77 | TGM2 (0.81) | KRASTGM2FUT5NT5EP2RY2 | |
| SCHEMBL376140 | 0.77 | TGM2 (0.81) | KRASTGM2FUT5NT5EP2RY2 | |
| Guanosine Triphosphate SCHEMBL44408 | 0.77 | TGM2 (0.81) | KRASTGM2FUT5NT5EP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154170-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154170-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | KRAS, NRAS, TP53 | KRAS 1/4885TGM2 3023/4885FUT5 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.